Nearly every SaaS product is either integrating AI or planning to do so. However, the term “AI” has become so broad that it’s ...
Novartis could lose years of patent protection in the US for its blockbuster multiple sclerosis therapy Gilenya, after a federal appeals verdict went against the company. The litigation revolves ...
Following its FDA approval in the summer, Tonix Pharma's fibromyalgia therapy Tonmya has been launched onto the market in the US, becoming the first new drug for the painful condition in more than 16 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback